Association of in-line digestive enzyme cartridge with enteral feeds on improvement in anthropometrics among pediatric patients with cystic fibrosis.

IF 2.1 4区医学 Q3 NUTRITION & DIETETICS

Nutrition in Clinical Practice Pub Date : 2024-08-01 Epub Date: 2024-03-16 DOI:10.1002/ncp.11142

Samarth Shrivastava, Karyn Shaw, MinJae Lee, Patricia Reitich, Stacie Hunter, Mary Klosterman, Meghana Sathe

{"title":"Association of in-line digestive enzyme cartridge with enteral feeds on improvement in anthropometrics among pediatric patients with cystic fibrosis.","authors":"Samarth Shrivastava, Karyn Shaw, MinJae Lee, Patricia Reitich, Stacie Hunter, Mary Klosterman, Meghana Sathe","doi":"10.1002/ncp.11142","DOIUrl":null,"url":null,"abstract":"Background: Approximately 85% of patients with cystic fibrosis (CF) have exocrine pancreatic insufficiency (EPI) with 10% requiring supplemental nighttime enteral tube feedings. Administration of pancreatic enzyme replacement therapy (PERT) with nighttime feedings is fraught with challenges. RELiZORB (Alcresta Therapeutics, Inc), an in-line lipase cartridge, delivers PERT continuously with enteral feedings. Outcomes related to the use of this in-line lipase cartridge are lesser known. This project evaluated anthropometrics related to in-line lipase cartridge use among pediatric patients with CF already receiving oral PERT therapy prior to nighttime enteral feedings.Methods: Retrospective chart review was performed on 29 patients with CF and EPI receiving supplemental tube feedings and utilizing in-line lipase cartridge for a continuous 12 month period between 2015 and 2019. Anthropometrics were evaluated 12 months before and after initiation of in-line lipase cartridge.Results: Compared with mean height z score at 6-months pre-in-line lipase cartridge, mean height z score at 6-months post-in-line-lipase cartridge (adjusted mean difference [AMD] = 0.2540; 95% CI = [0.0487, 0.4592]; P = 0.0153) and mean height z score at 12-months post-in-line lipase cartridge (AMD = 0.2684; 95% CI = [0.0203, 0.5166]; P = 0.0340) were significantly higher. Mean weight z score at 12-months post-in-line-lipase-cartridge neared statistical significance compared with 6-months pre-in-line lipase cartridge (AMD = 0.2816; 95% CI = [-0.0003, 0.5634]; P = 0.0502) when excluding seven patients with advanced lung disease (forced expiratory volume in the first second of expiration of 40%). Weight-for-length or body mass index did not significantly differ compared with pre-in-line lipase cartridge.Conclusion: Use of in-line lipase cartridge with enteral feeds improved anthropometrics, especially height, in pediatric patients with CF.","PeriodicalId":19354,"journal":{"name":"Nutrition in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ncp.11142","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Approximately 85% of patients with cystic fibrosis (CF) have exocrine pancreatic insufficiency (EPI) with 10% requiring supplemental nighttime enteral tube feedings. Administration of pancreatic enzyme replacement therapy (PERT) with nighttime feedings is fraught with challenges. RELiZORB (Alcresta Therapeutics, Inc), an in-line lipase cartridge, delivers PERT continuously with enteral feedings. Outcomes related to the use of this in-line lipase cartridge are lesser known. This project evaluated anthropometrics related to in-line lipase cartridge use among pediatric patients with CF already receiving oral PERT therapy prior to nighttime enteral feedings.

Methods: Retrospective chart review was performed on 29 patients with CF and EPI receiving supplemental tube feedings and utilizing in-line lipase cartridge for a continuous 12 month period between 2015 and 2019. Anthropometrics were evaluated 12 months before and after initiation of in-line lipase cartridge.

Results: Compared with mean height z score at 6-months pre-in-line lipase cartridge, mean height z score at 6-months post-in-line-lipase cartridge (adjusted mean difference [AMD] = 0.2540; 95% CI = [0.0487, 0.4592]; P = 0.0153) and mean height z score at 12-months post-in-line lipase cartridge (AMD = 0.2684; 95% CI = [0.0203, 0.5166]; P = 0.0340) were significantly higher. Mean weight z score at 12-months post-in-line-lipase-cartridge neared statistical significance compared with 6-months pre-in-line lipase cartridge (AMD = 0.2816; 95% CI = [-0.0003, 0.5634]; P = 0.0502) when excluding seven patients with advanced lung disease (forced expiratory volume in the first second of expiration of 40%). Weight-for-length or body mass index did not significantly differ compared with pre-in-line lipase cartridge.

Conclusion: Use of in-line lipase cartridge with enteral feeds improved anthropometrics, especially height, in pediatric patients with CF.

查看原文本刊更多论文

在线消化酶盒与肠道喂养对改善囊性纤维化儿科患者人体测量指标的影响。

背景：约 85% 的囊性纤维化（CF）患者存在胰腺外分泌功能不全（EPI），其中 10% 需要夜间补充肠管喂养。使用胰酶替代疗法（PERT）进行夜间喂养充满了挑战。RELiZORB（Alcresta Therapeutics 公司）是一种在线脂肪酶盒，可通过肠道喂养持续提供胰酶替代疗法。与使用这种在线脂肪酶盒相关的结果却鲜为人知。本项目评估了已在夜间肠内喂养前接受口服 PERT 治疗的 CF 儿科患者使用直插式脂肪酶盒的相关人体测量指标：在2015年至2019年连续12个月期间，对29名接受补充管喂养并使用在线脂肪酶盒的CF和EPI患者进行了回顾性病历审查。对使用在线脂肪酶盒前后12个月的人体测量进行了评估：与使用在线脂肪酶盒前6个月的平均身高z得分相比，使用在线脂肪酶盒后6个月的平均身高z得分（调整后平均差[AMD] = 0.2540；95% CI = [0.0487，0.4592]；P = 0.0153）和使用在线脂肪酶盒后12个月的平均身高z得分（AMD = 0.2684；95% CI = [0.0203，0.5166]；P = 0.0340）明显更高。如果排除七名肺部疾病晚期患者（第一秒用力呼气容积为 40%），在线脂肪酶盒后 12 个月的平均体重 Z 值与在线脂肪酶盒前 6 个月的平均体重 Z 值（AMD = 0.2816；95% CI = [-0.0003，0.5634]；P = 0.0502）相比，接近统计学意义。与使用在线脂肪酶盒前相比，体重身长或体重指数没有明显差异：结论：使用在线脂肪酶盒和肠道喂养可改善 CF 儿童患者的人体测量，尤其是身高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutrition in Clinical Practice 医学-营养学

CiteScore

6.00

自引率

9.70%

发文量

128

审稿时长

3 months

期刊介绍： NCP is a peer-reviewed, interdisciplinary publication that publishes articles about the scientific basis and clinical application of nutrition and nutrition support. NCP contains comprehensive reviews, clinical research, case observations, and other types of papers written by experts in the field of nutrition and health care practitioners involved in the delivery of specialized nutrition support. This journal is a member of the Committee on Publication Ethics (COPE).